Literature DB >> 21411814

Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.

Heike Immervoll1, Dag Hoem, Ole Johnny Steffensen, Hrvoje Miletic, Anders Molven.   

Abstract

Tumor-initiating cells of pancreatic ductal adenocarcinoma (PDAC) have been isolated based on expression of either CD133 or CD44. The authors aimed to visualize pancreatic cells simultaneously expressing both these cell surface markers by employing the same antibodies commonly used in cell-sorting studies. Normal and diseased pancreatic tissue, including 51 PDAC cases, were analyzed. CD44 and CD133 expression was determined by immunohistochemical double staining on formalin-fixed material and subcellular protein distribution evaluated by immunofluorescence/confocal microscopy. In the normal pancreas, CD44 and CD133 were coexpressed in the centroacinar regions but in non-overlapping subcellular compartments. As expected, CD44 was found mainly basolaterally, whereas CD133 was present on the apical/endoluminal membrane. This was also the case in chronically inflamed/atrophic pancreatic tissue and in PDAC. In some malignant ducts, CD44 was found at the apical cell membrane adjacent to but never overlapping with CD133 expression. CD44 level was significantly associated with the patient's lymph node status. In conclusion, a CD44+/CD133+ cell population does exist in the normal and neoplastic pancreas. The preferentially centroacinar localization of the doubly positive cells in the normal parenchyma suggests that this population could be of particular interest in attempts to identify tumor-initiating cells in PDAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411814      PMCID: PMC3201142          DOI: 10.1369/0022155411398275

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  80 in total

1.  Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells.

Authors:  A Weigmann; D Corbeil; A Hellwig; W B Huttner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

2.  AC133, a novel marker for human hematopoietic stem and progenitor cells.

Authors:  A H Yin; S Miraglia; E D Zanjani; G Almeida-Porada; M Ogawa; A G Leary; J Olweus; J Kearney; D W Buck
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113

3.  Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study.

Authors:  E M Castellà; A Ariza; I Ojanguren; J L Mate; X Roca; A Fernández-Vasalo; J J Navas-Palacios
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

4.  CD44 isoforms with exon v6 and metastasis of primary N0M0 breast carcinomas.

Authors:  N Guriec; B Gairard; L Marcellin; A Wilk; H Caldéroli; R Renaud; J P Bergerat; F Oberling
Journal:  Breast Cancer Res Treat       Date:  1997-07       Impact factor: 4.872

5.  Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.

Authors:  J A Reeder; D C Gotley; M D Walsh; J Fawcett; T M Antalis
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

6.  Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate.

Authors:  A C Gao; W Lou; J P Sleeman; J T Isaacs
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

7.  [Expression of CD44 and isoforms v4, v5, v6, v7, v10--new prognostic parameters in ductal pancreatic carcinoma?].

Authors:  T Böttger; H Maschek; W Gottwald; M Lobo; W Brenner; T Junginger
Journal:  Chirurg       Date:  1998-10       Impact factor: 0.955

8.  Expression of CD44 variant 6 and lymphatic invasion: importance to lymph node metastasis in gastric cancer.

Authors:  K Kurozumi; T Nishida; K Nakao; M Nakahara; M Tsujimoto
Journal:  World J Surg       Date:  1998-08       Impact factor: 3.352

9.  CD44 variant isoform expression and breast cancer prognosis.

Authors:  Y Tokue; Y Matsumura; N Katsumata; T Watanabe; D Tarin; T Kakizoe
Journal:  Jpn J Cancer Res       Date:  1998-03

10.  Expression of CD44 variants and its association with survival in pancreatic cancer.

Authors:  T Gotoda; Y Matsumura; H Kondo; D Saitoh; Y Shimada; T Kosuge; Y Kanai; T Kakizoe
Journal:  Jpn J Cancer Res       Date:  1998-10
View more
  15 in total

1.  Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers.

Authors:  Randy S Haun; Charles M Quick; Eric R Siegel; Ilangovan Raju; Samuel G Mackintosh; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

2.  Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

Authors:  Ling Li; Xinbao Hao; Jun Qin; Wenhua Tang; Fengtian He; Amber Smith; Min Zhang; Diane M Simeone; Xiaotan T Qiao; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Gastroenterology       Date:  2014-01-05       Impact factor: 22.682

3.  Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.

Authors:  Jianhui Zhu; Song Nie; Jing Wu; David M Lubman
Journal:  J Proteome Res       Date:  2013-05-29       Impact factor: 4.466

Review 4.  Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight.

Authors:  Norihiro Sato; Shiro Kohi; Keiji Hirata; Michael Goggins
Journal:  Cancer Sci       Date:  2016-03-18       Impact factor: 6.716

5.  Pediatric sarcomas.

Authors:  Junhua Cao; Qi An; Lei Wang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

6.  Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.

Authors:  L Durko; W Wlodarski; O Stasikowska-Kanicka; M Wagrowska-Danilewicz; M Danilewicz; P Hogendorf; J Strzelczyk; E Malecka-Panas
Journal:  Dis Markers       Date:  2017-06-04       Impact factor: 3.434

7.  Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors.

Authors:  Sanne Hindriksen; Maarten F Bijlsma
Journal:  Cancers (Basel)       Date:  2012-10-12       Impact factor: 6.639

8.  Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.

Authors:  Kazuya Shimizu; Sachie Chiba; Yuichi Hori
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

9.  Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.

Authors:  Tatsuzo Mizukami; Hirofumi Kamachi; Tomoko Mitsuhashi; Yosuke Tsuruga; Yutaka Hatanaka; Toshiya Kamiyama; Yoshihiro Matsuno; Akinobu Taketomi
Journal:  BMC Cancer       Date:  2014-09-21       Impact factor: 4.430

10.  Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.

Authors:  Ya-Chin Hou; Ying-Jui Chao; Hui-Ling Tung; Hao-Chen Wang; Yan-Shen Shan
Journal:  Cancer       Date:  2014-05-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.